Phase 1 biotech developing oligonucleotide therapies for neuromuscular diseases.
Industry: Health Care
Latest Trade: $6.79 0.00 (0.0%)
First Day Return: +7.4%
Return from IPO: -43.4%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 04/15/2022 |
Offer Price | $12.00 |
Price Range $13.00 - $15.00 | |
Offer Shares (mm) | 9.0 |
Deal Size ($mm) | $108 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 05/05/2022 |
Offer Price | $12.00 |
Price Range $13.00 - $15.00 | |
Offer Shares (mm) | 9.0 |
Deal Size ($mm) | $108 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
BofA Securities |
Leerink Partners |
more |
Company Data | |
---|---|
Headquarters | Cambridge, MA, United States |
Founded | 2018 |
Employees at IPO | 31 |
Website pepgen.com |